Today, the U.S. Food and Drug Administration has granted approval for a new indication for Wegovy (semaglutide) injection aimed at reducing the risk of cardiovascular death, heart attack, and stroke in adults grappling with cardiovascular disease coupled with obesity or being overweight. This approval marks a significant milestone as Wegovy becomes the pioneer weight loss medication endorsed to aid in averting life-threatening cardiovascular events among this demographic.

Highlights

• Wegovy, containing semaglutide, is now sanctioned by the FDA to diminish cardiovascular risk in adults with cardiovascular disease and either obesity or overweight.
• The approval follows a comprehensive study involving over 17,600 participants, where Wegovy demonstrated a significant reduction in major adverse cardiovascular events compared to the placebo group.
• Despite its efficacy, Wegovy carries warnings, including a boxed warning regarding the risk of thyroid C-cell tumors and cautionary notes on pancreatitis, gallbladder issues, low blood sugar, and other potential side effects.
• Common side effects of Wegovy encompass nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue, among others.
• The FDA approval was granted to Novo Nordisk A/S, the pharmaceutical company behind Wegovy.

Obesity and being overweight afflict about 70% of American adults, predisposing them to heightened risks of premature death and various health complications, including cardiovascular ailments. Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity at the FDA's Center for Drug Evaluation and Research, lauded the approval, emphasizing the critical advancement it signifies for public health.

However, the prescribing information for Wegovy incorporates a boxed warning to apprise healthcare professionals and patients about the potential risk of thyroid C-cell tumors. Consequently, individuals with a personal or family history of medullary thyroid carcinoma or a rare condition called Multiple Endocrine Neoplasia syndrome type 2 should avoid using Wegovy.

Moreover, Wegovy should not be administered to individuals with a history of severe allergic reactions to semaglutide or any of its components. Patients experiencing signs of pancreatitis or gallstones should promptly consult their healthcare provider, while healthcare professionals are urged to monitor patients for various conditions such as kidney disease, diabetic retinopathy, and depression.

Wegovy's journey to FDA approval involved a multi-national, multi-center, placebo-controlled double-blind trial, where it demonstrated its ability to significantly mitigate the risk of major adverse cardiovascular events. However, it is imperative for both healthcare providers and patients to remain vigilant about potential side effects and adhere to safety precautions.

Aside from its latest indication, Wegovy has also been greenlit to aid in weight reduction and long-term weight maintenance in specific adult and pediatric populations grappling with obesity, provided it's used alongside a reduced-calorie diet and increased physical activity.